1. Bottomley SS, Fleming MD. Sideroblastic anemia: diagnosis and management. Hematol Oncol Clin North Am. 2014;28(4):653-670, v.
2. Yamamoto M, Yew NS, Federspiel M, Dodgson JB, Hayashi N, Engel JD. Isolation of recombinant cDNAs encoding chicken erythroid delta-aminolevulinate synthase. Proc Natl Acad Sci U S A. 1985;82(11):3702-3706.
3. Ducamp S, Fleming MD. The molecular genetics of sideroblastic anemia. Blood. 2019;133(1):59-69.
4. Aivado M, Gattermann N, Rong A, et al. X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns. Blood Cells Mol Dis. 2006;37(1):40-45.
5. Sankaran VG, Ulirsch JC, Tchaikovskii V, et al. X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. J Clin Invest. 2015;125(4):1665-1669.
6. Katsurada T, Kawabata H, Kawabata D, et al. A Japanese family with X-linked sideroblastic anemia affecting females and manifesting as macrocytic anemia. Int J Hematol. 2016;103(6):713-717.
7. Rose C, Callebaut I, Pascal L, et al. Lethal ALAS2 mutation in males X-linked sideroblastic anaemia. Br J Haematol. 2017;178(4):648-651.
8. Cazzola M, May A, Bergamaschi G, Cerani P, Rosti V, Bishop DF. Familialskewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood. 2000;96(13):4363-4365.
9. Bergmann AK, Campagna DR, McLoughlin EM, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer. 2010;54(2):273-278.
10. Ohba R, Furuyama K, Yoshida K, et al. Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS). Ann Hematol. 2013;92(1):1-9.
11. Astner I, Schulze JO, van den Heuvel J, Jahn D, Schubert WD, Heinz DW. Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans. EMBO J. 2005;24(18):3166-3177.
12. Ishida H, Imamura T, Morimoto A, Fujiwara T, Harigae H. Five-aminolevulinic acid: New approach for congenital sideroblastic anemia. Pediatr Int. 2018;60(5):496-497.
13. Nakajima O, Takahashi S, Harigae H, et al. Heme deficiency in erythroid lineage causes differentiation arrest and cytoplasmic iron overload. Embo j. 1999;18(22):6282- 6289.
14. Nakajima O, Okano S, Harada H, et al. Transgenic rescue of erythroid 5- aminolevulinate synthase-deficient mice results in the formation of ring sideroblasts and siderocytes. Genes Cells. 2006;11(6):685-700.
15. Harigae H, Nakajima O, Suwabe N, et al. Aberrant iron accumulation and oxidized status of erythroid-specific delta-aminolevulinate synthase (ALAS2)-deficient definitive erythroblasts. Blood. 2003;101(3):1188-1193.
16. Hatta S, Fujiwara T, Yamamoto T, et al. A defined culture method enabling the establishment of ring sideroblasts from induced pluripotent cells of X-linked sideroblastic anemia. Haematologica. 2018;103(5):e188-e191.
17. Kaneko K, Kubota Y, Nomura K, et al. Establishment of a cell model of X-linked sideroblastic anemia using genome editing. Exp Hematol. 2018;65:57-68 e52.
18. Saito K, Fujiwara T, Hatta S, et al. Generation and Molecular Characterization of Human Ring Sideroblasts: a Key Role of Ferrous Iron in Terminal Erythroid Differentiation and Ring Sideroblast Formation. Mol Cell Biol. 2019;39(7).
19. Okita K, Yamakawa T, Matsumura Y, et al. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2013;31(3):458-466.
20. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.
21. Boudewijns M, van Dongen JJ, Langerak AW. The human androgen receptor Xchromosome inactivation assay for clonality diagnostics of natural killer cell proliferations. J Mol Diagn. 2007;9(3):337-344.
22. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgenreceptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51(6):1229-1239.
23. Grigoriadis AE, Kennedy M, Bozec A, et al. Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood. 2010;115(14):2769-2776.
24. Nishizawa M, Chonabayashi K, Nomura M, et al. Epigenetic Variation between Human Induced Pluripotent Stem Cell Lines Is an Indicator of Differentiation Capacity. Cell Stem Cell. 2016;19(3):341-354.
25. Kurita R, Suda N, Sudo K, et al. Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells. PLoS One. 2013;8(3):e59890.
26. Kotini AG, Chang CJ, Chow A, et al. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell. 2017;20(3):315-328 e317.
27. Tokutomi T, Fukushima A, Yamamoto K, Bansho Y, Hachiya T, Shimizu A. ftreeGC: a questionnaire-based family tree-creation software for genetic counseling and genome cohort studies. BMC Med Genet. 2017;18(1):71.
28. Huang P, Zhao Y, Zhong J, et al. Putative regulators for the continuum of erythroid differentiation revealed by single-cell transcriptome of human BM and UCB cells. Proc Natl Acad Sci U S A. 2020;117(23):12868-12876.
29. Ng KM, Mok PY, Butler AW, et al. Amelioration of X-Linked Related Autophagy Failure in Danon Disease With DNA Methylation Inhibitor. Circulation. 2016;134(18):1373-1389.
30. Donker AE, Raymakers RA, Nieuwenhuis HK, et al. X-linked sideroblastic anaemia due to ALAS₂ mutations in the Netherlands: a disease in disguise. Neth J Med. 2014;72(4):210-217.
31. Cotter PD, May A, Fitzsimons EJ, et al. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest. 1995;96(4):2090-2096.
32. Fujiwara T, Fukuhara N, Ichikawa S, et al. A novel heterozygous ALAS2 mutation in a female with macrocytic sideroblastic anemia resembling myelodysplastic syndrome with ring sideroblasts: a case report and literature review. Ann Hematol. 2017;96(11):1955-1957.
33. Ananiev G, Williams EC, Li H, Chang Q. Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as in vitro disease model. PLoS One. 2011;6(9):e25255.
34. Řeboun M, Rybová J, Dobrovolný R, et al. X-Chromosome Inactivation Analysis in Different Cell Types and Induced Pluripotent Stem Cells Elucidates the Disease Mechanism in a Rare Case of Mucopolysaccharidosis Type II in a Female. Folia Biol (Praha). 2016;62(2):82-89.
35. Trakarnsanga K, Wilson MC, Heesom KJ, Andrienko TN, Srisawat C, Frayne J. Secretory factors from OP9 stromal cells delay differentiation and increase the expansion potential of adult erythroid cells in vitro. Sci Rep. 2018;8(1):1983.
36. Fujiwara T, Okamoto K, Niikuni R, et al. Effect of 5-aminolevulinic acid on erythropoiesis: a preclinical in vitro characterization for the treatment of congenital sideroblastic anemia. Biochem Biophys Res Commun. 2014;454(1):102-108